دورية أكاديمية
Development and Evaluation of a Self-Nanoemulsifying Drug Delivery System for Sinapic Acid with Improved Antiviral Efficacy against SARS-CoV-2.
| العنوان: | Development and Evaluation of a Self-Nanoemulsifying Drug Delivery System for Sinapic Acid with Improved Antiviral Efficacy against SARS-CoV-2. |
|---|---|
| المؤلفون: | Alhadrami HA; Faculty of Applied Medical Sciences, Department of Medical Laboratory Technology, King Abdulaziz University, P.O. Box 80402, Jeddah 21589, Saudi Arabia.; King Fahd Medical Research Centre, King Abdulaziz University, P.O. Box 80402, Jeddah 21589, Saudi Arabia.; Molecular Diagnostics Laboratory, King Abdulaziz University Hospital, P.O. Box 80402, Jeddah 21589, Saudi Arabia., El-Din ASGS; Department of Pharmaceutics, Faculty of Pharmacy, Delta University for Science & Technology, Gamasa City 35712, Egypt., Hassan HM; Department of Pharmacognosy, Faculty of Pharmacy, Nahda University, Beni-Suef 62513, Egypt.; Department of Pharmacognosy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt., Sayed AM; Department of Pharmacognosy, Faculty of Pharmacy, Nahda University, Beni-Suef 62513, Egypt., Alhadrami AH; School of Computing, Engineering & Physical Sciences, University of the West of Scotland, Paisley PA1 2BE, UK., Rateb ME; School of Computing, Engineering & Physical Sciences, University of the West of Scotland, Paisley PA1 2BE, UK., Naguib DM; Department of Pharmaceutics, Faculty of Pharmacy, Nahda University (NUB), Beni-Suef 62513, Egypt. |
| المصدر: | Pharmaceutics [Pharmaceutics] 2023 Oct 25; Vol. 15 (11). Date of Electronic Publication: 2023 Oct 25. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101534003 Publication Model: Electronic Cited Medium: Print ISSN: 1999-4923 (Print) Linking ISSN: 19994923 NLM ISO Abbreviation: Pharmaceutics Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI |
| مستخلص: | This study aimed to develop a self-nanoemulsifying drug delivery system (SNE) for sinapic acid (SA) to improve its solubility and antiviral activity. Optimal components for the SA-SNE formulation were selected, including Labrafil as the oil, Cremophor EL as the surfactant, and Transcutol as the co-surfactant. The formulation was optimized using surface response design, and the optimized SA-SNE formulation exhibited a small globule size of 83.6 nm, high solubility up to 127.1 ± 3.3, and a 100% transmittance. In vitro release studies demonstrated rapid and high SA release from the formulation. Pharmacokinetic analysis showed improved bioavailability by 2.43 times, and the optimized SA-SNE formulation exhibited potent antiviral activity against SARS-CoV-2. The developed SA-SNE formulation can enhance SA's therapeutic efficacy by improving its solubility, bioavailability, and antiviral activity. Further in silico, modeling, and Gaussian accelerated molecular dynamics ( G aMD)-based studies revealed that SA could interact with and inhibit the viral main protease (M pro ). This research contributes to developing effective drug delivery systems for poorly soluble drugs like SA, opening new possibilities for their application via nebulization in SARS-CoV-2 therapy. |
| References: | AAPS PharmSciTech. 2014 Apr;15(2):456-64. (PMID: 24452500) Drug Des Devel Ther. 2017 Nov 28;11:3377-3388. (PMID: 29238164) Pharmaceutics. 2021 Mar 30;13(4):. (PMID: 33808316) Eur J Pharm Sci. 2016 Mar 31;85:112-22. (PMID: 26851382) Drug Dev Ind Pharm. 2013 May;39(5):696-703. (PMID: 22616839) Eur J Nutr. 2020 Jun;59(4):1275-1293. (PMID: 31115680) Mol Biol Rep. 2021 Apr;48(4):3733-3745. (PMID: 33988797) Int J Nanomedicine. 2015 Jun 05;10:3865-77. (PMID: 26089663) J Pharm Sci. 1971 Sep;60(9):1281-302. (PMID: 4935981) J Microencapsul. 2022 Sep;39(6):563-574. (PMID: 36222429) Plants (Basel). 2021 Jan 08;10(1):. (PMID: 33430128) Int J Pharm. 2009 Jun 5;374(1-2):66-72. (PMID: 19446761) J Liposome Res. 2018 Jun;28(2):149-160. (PMID: 28287014) Food Funct. 2020 Aug 1;11(8):7231-7244. (PMID: 32760968) Ther Deliv. 2022 Jan;13(1):31-49. (PMID: 34766509) Pharm Res. 2004 Feb;21(2):201-30. (PMID: 15032302) Pharmaceutics. 2020 Dec 09;12(12):. (PMID: 33317067) Eur J Med Chem. 2022 Nov 5;241:114629. (PMID: 35961070) J Chem Theory Comput. 2017 Jan 10;13(1):9-19. (PMID: 28034310) Front Plant Sci. 2021 Jan 12;11:604349. (PMID: 33510749) Acta Pharmacol Sin. 2020 Sep;41(9):1167-1177. (PMID: 32737471) J Immunol Methods. 1983 Dec 16;65(1-2):55-63. (PMID: 6606682) N Engl J Med. 2003 May 15;348(20):1967-76. (PMID: 12690091) J Virol. 2004 Mar;78(6):3162-9. (PMID: 14990737) Crit Rev Ther Drug Carrier Syst. 2008;25(1):63-116. (PMID: 18540836) J Comput Chem. 2005 Dec;26(16):1781-802. (PMID: 16222654) Eur J Pharm Sci. 2006 May;28(1-2):67-76. (PMID: 16472995) Environ Res. 2023 Mar 1;220:115075. (PMID: 36566967) Int J Pharm. 2005 Sep 14;301(1-2):199-208. (PMID: 16024189) J Control Release. 2003 Jun 5;90(1):37-48. (PMID: 12767705) J Sep Sci. 2023 Jan;46(2):e2200602. (PMID: 36377517) Int Immunopharmacol. 2023 Aug;121:110341. (PMID: 37301118) J Clin Microbiol. 1990 Mar;28(3):495-503. (PMID: 1691208) Front Chem. 2021 May 14;9:664602. (PMID: 34055737) J Chem Inf Model. 2021 May 24;61(5):2302-2312. (PMID: 33829781) J Colloid Interface Sci. 2007 Oct 15;314(2):712-7. (PMID: 17585927) Biomol Ther (Seoul). 2022 Sep 1;30(5):409-417. (PMID: 35611585) Expert Opin Drug Deliv. 2010 Apr;7(4):445-60. (PMID: 20201713) J Biomed Nanotechnol. 2013 Dec;9(12):1996-2006. (PMID: 24266255) Nanomaterials (Basel). 2020 Jan 12;10(1):. (PMID: 31940900) J Chem Theory Comput. 2020 Nov 10;16(11):7207-7218. (PMID: 33112150) Food Chem Toxicol. 2021 Oct;156:112443. (PMID: 34329744) Oxid Med Cell Longev. 2020 Jul 11;2020:1436858. (PMID: 32765804) Int J Pharm. 2022 Jun 25;622:121852. (PMID: 35618179) Mol Pharm. 2013 Aug 5;10(8):3057-66. (PMID: 23837910) Int J Pharm. 2004 Apr 1;273(1-2):63-73. (PMID: 15010131) Drug Dev Ind Pharm. 2000 May;26(5):523-9. (PMID: 10789064) Pharmaceutics. 2019 Dec 01;11(12):. (PMID: 31805660) Inflammopharmacology. 2023 Feb;31(1):301-320. (PMID: 36609718) Pharmaceutics. 2022 Jan 31;14(2):. (PMID: 35214068) Drug Des Devel Ther. 2021 Jul 16;15:3071-3093. (PMID: 34305395) Drug Dev Ind Pharm. 2020 Nov;46(11):1787-1799. (PMID: 32896171) Pharmaceuticals (Basel). 2023 Feb 13;16(2):. (PMID: 37259427) J Am Chem Soc. 2015 Feb 25;137(7):2695-703. (PMID: 25625324) Biol Pharm Bull. 2011;34(8):1179-86. (PMID: 21804203) J Diabetes Metab Disord. 2022 Jan 6;21(1):293-303. (PMID: 35673480) Biotechnol J. 2020 Jan;15(1):e1900172. (PMID: 31486583) Pharmaceutics. 2022 Oct 12;14(10):. (PMID: 36297609) |
| معلومات مُعتمدة: | (8-8)2120191) by Jameel Fund for Infectious Disease Research and Innovation |
| فهرسة مساهمة: | Keywords: GaMD; Mpro; SARS-CoV-2; self-nanoemulsifying drug delivery system; sinapic acid |
| تواريخ الأحداث: | Date Created: 20231125 Latest Revision: 20231127 |
| رمز التحديث: | 20231127 |
| مُعرف محوري في PubMed: | PMC10674535 |
| DOI: | 10.3390/pharmaceutics15112531 |
| PMID: | 38004511 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!